Patents Assigned to CONSTELLATION PHARMACEUTICALS, INC.
-
Patent number: 11919912Abstract: Provided are novel compounds of Formula (I): Formula (I); and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.Type: GrantFiled: May 17, 2019Date of Patent: March 5, 2024Assignee: Constellation Pharmaceuticals, Inc.Inventors: Alexandre Côté, Avinash Khanna, Ludivine Moine
-
Patent number: 11547695Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.Type: GrantFiled: April 27, 2021Date of Patent: January 10, 2023Assignee: Constellation Pharmaceuticals, Inc.Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
-
Patent number: 11459315Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compostions thereof, which are useful for treating a variety of conditions associated with methyl modifying enzymes.Type: GrantFiled: November 8, 2018Date of Patent: October 4, 2022Assignee: Constellation Pharmaceuticals, Inc.Inventors: Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
-
Patent number: 11414384Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).Type: GrantFiled: February 15, 2019Date of Patent: August 16, 2022Assignee: Constellation Pharmaceuticals, Inc.Inventors: Jonathan E. Wilson, Julian R. Levell
-
Publication number: 20220127265Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: January 6, 2022Publication date: April 28, 2022Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
-
Patent number: 11274090Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).Type: GrantFiled: February 15, 2019Date of Patent: March 15, 2022Assignee: Constellation Pharmaceuticals, Inc.Inventors: Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
-
Patent number: 11274095Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.Type: GrantFiled: April 23, 2020Date of Patent: March 15, 2022Assignee: Constellation Pharmaceuticals, Inc.Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
-
Patent number: 11247989Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: November 21, 2018Date of Patent: February 15, 2022Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
-
Patent number: 11168070Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: May 28, 2020Date of Patent: November 9, 2021Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Patent number: 11013718Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.Type: GrantFiled: November 1, 2019Date of Patent: May 25, 2021Assignee: Constellation Pharmaceuticals, Inc.Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
-
Patent number: 10918646Abstract: The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.Type: GrantFiled: October 7, 2020Date of Patent: February 16, 2021Assignee: Constellation Pharmaceuticals, Inc.Inventors: Adrian Senderowicz, Michael Cooper
-
Publication number: 20200399244Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: May 28, 2020Publication date: December 24, 2020Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Patent number: 10696655Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: November 21, 2018Date of Patent: June 30, 2020Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Patent number: 10689371Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.Type: GrantFiled: April 18, 2019Date of Patent: June 23, 2020Assignee: Constellation Pharmaceuticals, Inc.Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
-
Publication number: 20200069677Abstract: Provided herein are methods of treating cancers characterized by a high expression of GFIIB, comprising administering a therapeutically effective amount of a KDMIA inhibitor.Type: ApplicationFiled: December 8, 2017Publication date: March 5, 2020Applicants: Constellation Pharmaceuticals, Inc., Constellation Pharmaceuticals, Inc.Inventors: John McGrath, Patrick Trojer
-
Patent number: 10577350Abstract: The present disclosure relates to a crystalline Forms A, B, and C of (R)—N-((4-methoxy-6-methyl-2-oxo-1,2-di-hydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, each of which are useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: August 25, 2016Date of Patent: March 3, 2020Assignee: Constellation Pharmaceuticals, Inc.Inventors: Brian K. Albrecht, Alisha Arrigo, Donald Corson, Victor S. Gehling, Bruno Patrice Haché, Jean-Christophe Harmange, Jonathan Lane
-
Patent number: 10526287Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.Type: GrantFiled: April 22, 2016Date of Patent: January 7, 2020Assignee: Constellation Pharmaceuticals, Inc.Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Rishi G. Vaswani
-
Patent number: 10517849Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.Type: GrantFiled: October 26, 2017Date of Patent: December 31, 2019Assignee: Constellation Pharmaceuticals, Inc.Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
-
Patent number: 10457640Abstract: Provided herein are synthetic methods for the preparation of EZH2 inhibitors.Type: GrantFiled: October 18, 2017Date of Patent: October 29, 2019Assignee: Constellation Pharmaceuticals, Inc.Inventors: Rishi G. Vaswani, Michael Charles Hewitt
-
Publication number: 20190274998Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.Type: ApplicationFiled: October 26, 2017Publication date: September 12, 2019Applicant: Constellation Pharmaceuticals, Inc.Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna